Abstract
Background
Esophagectomy is the mainstay of curative treatment for localized esophageal cancer. However, what constitutes cure is not well defined. This study was undertaken to characterize actual 5-year survivors following esophagectomy and to determine prognostic factors for disease-specific survival (DSS) from 60 months.
Materials and Methods
Between 1987 and 2004, 398 consecutive patients underwent esophagectomy and had potential for 5 years follow-up. Clinicopathological factors associated with DSS from 5 years onward were analyzed.
Results
Median DSS was 25 months. Neoadjuvant therapy was administered to 159 of 398 (40%). There were 114 of 398 (29%) actual 5-year survivors. On multivariate analysis, 5-year survivors were significantly more likely to have lower T classification, N classification, and R0 resections compared with patients who died less than 5 years after surgery. There were 66 of 398 patients (17%) with positive margins, and 6 of these were 5-year survivors. Of the 114 5-year survivors, 17 (15%) subsequently died of esophageal cancer. Prognostic factors for DSS after surviving 5 years were age and T classification for patients treated with neoadjuvant therapy and surgery alone, respectively. Powerful prognostic factors from time of treatment, including nodal status, were no longer prognostic factors after surviving to 5 years.
Conclusions
No single clinicopathological variable negated survival to 5 years. Prognostication once surviving 5 years is difficult. The majority of 5-year survivors can be considered cured of esophageal cancer.
Similar content being viewed by others
References
Law S, Kwong DL, Kwok KF, Wong KH, Chu KM, Sham JS, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238:339–347; discussion 347–8.
Stein HJ, von Rahden BH, Siewert JR. Survival after oesophagectomy for cancer of the oesophagus. Langenbecks Arch Surg. 2005;390:280–5.
Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376–85.
Pohl H, Welch G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–6.
Blot W, Devesa S, Kneller R, Fraumeni J. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287–9.
Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2007;57:43–66.
Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520–30; discussion 530–1.
Altorki NK, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236:177–83.
Watson A. Operable esophageal cancer: Current results from the West. World J Surg. 1994;18:361–6.
Portale G, Hagen JA, Peters JH, Chan LS, DeMeester SR, Gandamihardja TA, et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg. 2006;202:588–96; discussion 596–8.
Hulscher JB. Transthoracic versus transhiatal resection for carcinoma of the esophagus: A meta-analysis. Ann Thorac Surg. 2001;72:306–13.
Tachibana M, Kinugasa S, Yoshimura H, Shibakita M, Tonomoto Y, Dhar DK, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg. 2005;189:98–109.
Green FL, Page DL, Fleming ID. AJCC cancer staging manual. New York, NY: Springer-Verlag, 2002.
Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15:2894–902.
Siewert JR, Stein HJ, Feith M, Bruecher BLDM, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: Lessons from more than 1000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234:360–9.
Dubecz A, Molena D, Peters, JH. Modern surgery for esophageal cancer. Gastroenterol Clin North Am. 2008;37:965–87.
Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.
Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction. Ann Surg. 2000;232:353–61.
Smithers BM, Gotley DC, Martin I, Thomas JM. Comparison of the outcomes between open and minimally invasive esophagectomy. Ann Surg. 2007;245:–232–40.
Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003;4:481–8.
Leibman S, Smithers BM, Gotley DC, Martin I, Thomas J. Minimally invasive esophagectomy: short- and long-term outcomes. Surg Endosc. 2006;20:428–33.
Sutton DN, Wayman J, Griffin SM. Learning curve for oesophageal cancer surgery. Br J Surg. 1998;85:1399–402.
Burmeister B, Smithers BM, Gebski V. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2006;6:659–68.
Conlon KC, Klimstra MD, Brennan M. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Ann Surg. 1996;223:273–9.
Hochwald SN, Kim S, Klimstra MD, Brennan MF, Karpeh MS. Analysis of 154 actual five-year survivors of gastric cancer. J Gastrointest Surg. 2000;4:520–5.
Vorburger SA, Ubersax L, Schmid SW, Balli M, Candinas D, Seiler CA. Long-term follow-up after complete resection of well-differentiated cancer confined to the thyroid gland. Ann Surg Oncol. 2009;16:2862–74.
Karakiewicz PI, Jeldres C, Suardi N, Hutterer GC, Perrotte P, Capitanio U, et al. Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J. 2008;2:610–7.
Zhang DW, Cheng GY, Huang GJ, Zhang RG, Liu XY, Mao YS, et al. Operable squamous esophageal cancer: current results from the East. World J Surg. 1994;18:347–54.
Omundsen M, Babor R, Johnston P. Outcomes after oesophagogastrectomy for carcinoma of the oesophagus. ANZ J Surg. 2007;77:37–9.
Tomlinson J, Jarnagin W, DeMatteo R, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–80.
Acknowledgment
We would like to thank Dr. Ian Martin for his clinical contributions and recruitment of patients. Research funding: Paul Mackay Bolton Scholarship 2009, Royal Australasian College of Surgeons.
Financial Disclosure
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hirst, J., Smithers, B.M., Gotley, D.C. et al. Defining Cure for Esophageal Cancer: Analysis of Actual 5-Year Survivors Following Esophagectomy. Ann Surg Oncol 18, 1766–1774 (2011). https://doi.org/10.1245/s10434-010-1508-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-010-1508-z